The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors （PDE5-1s） and （x-blockers used alone or combined for the treatment of lower urinary tract...The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors （PDE5-1s） and （x-blockers used alone or combined for the treatment of lower urinary tract symptoms （LUTS） due to benign prostatic hyperplasia （BPH）. An electronic search of PubMed, Cochrane Library and Embase up to January 2014 was performed to identify randomized controlled trials comparing the efficacy and safety of PDE5-Is and （x-blockers for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, which assessed IPSS score, maximum flow rate, postvoided residual urine, quality of life and Erectile Function （IIEF） score as outcomes. Data were analyzed by fixed or random effect models using Cochrane Collaboration review manager software. A total of 12 studies were included, Our novel data demonstrated that there was a trend that （x-blockers were more efficacious than PDE5-Is on decreasing IPSS score and increasing maximum flow rate. （x-blockers were significantly more effective than PDE5-Is on reduction of postvoided residual urine with a mean difference of 3.67 （95% CI 1.56 to 5.77, P = 0.0006） and PDE5-Is showed greater effect than （x-blockers on increasing IIEF score with a mean difference of 9.82 （95% CI 3.80 to 15.85, P = 0.001）. In conclusion, our novel data demonstrated that PDE5-Is plus ABs ranked the highest on the improvement of LUTS/BPH. PDE5-Is monotherapy was also effective in this kind of disorder except less reduction of PVR than ABs, In addition, both combined- or mono-therapy were safe.展开更多
文摘The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors （PDE5-1s） and （x-blockers used alone or combined for the treatment of lower urinary tract symptoms （LUTS） due to benign prostatic hyperplasia （BPH）. An electronic search of PubMed, Cochrane Library and Embase up to January 2014 was performed to identify randomized controlled trials comparing the efficacy and safety of PDE5-Is and （x-blockers for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia, which assessed IPSS score, maximum flow rate, postvoided residual urine, quality of life and Erectile Function （IIEF） score as outcomes. Data were analyzed by fixed or random effect models using Cochrane Collaboration review manager software. A total of 12 studies were included, Our novel data demonstrated that there was a trend that （x-blockers were more efficacious than PDE5-Is on decreasing IPSS score and increasing maximum flow rate. （x-blockers were significantly more effective than PDE5-Is on reduction of postvoided residual urine with a mean difference of 3.67 （95% CI 1.56 to 5.77, P = 0.0006） and PDE5-Is showed greater effect than （x-blockers on increasing IIEF score with a mean difference of 9.82 （95% CI 3.80 to 15.85, P = 0.001）. In conclusion, our novel data demonstrated that PDE5-Is plus ABs ranked the highest on the improvement of LUTS/BPH. PDE5-Is monotherapy was also effective in this kind of disorder except less reduction of PVR than ABs, In addition, both combined- or mono-therapy were safe.
